The FDA has granted 510(k) clearance to Roche Diagnostics for its Elecsys EBV VCA IgG assay, an in vitro diagnostic test for Epstein-Barr Virus antibodies. This expands the company's infectious disease diagnostics portfolio.
The U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Elecsys EBV VCA IgG assay developed by Roche Diagnostics. The traditional 510(k) clearance, granted on October 2, 2026, deems the device substantially equivalent to a predicate device, allowing its commercial distribution in the United States.
This in vitro diagnostic device is designed to detect IgG antibodies to the Epstein-Barr Virus Viral Capsid Antigen (EBV VCA). The specific intended use and clinical applications, beyond general infectious disease diagnostics, have not yet been publicly disclosed by Roche Diagnostics.
Device Classification and Regulatory Pathway
The Elecsys EBV VCA IgG assay falls under product code LSE, indicating its classification as an antigen, antibody, or nucleic acid detection system for Epstein-Barr virus. The FDA's Microbiology advisory committee was involved in its review, consistent with its role in infectious disease diagnostics.
Regulated under 21 CFR 866.3235, this device is categorized as Class I, a classification typically reserved for devices with lower potential for risk to patients. The traditional 510(k) pathway, rather than De Novo or PMA, reflects the agency's determination that the device is substantially equivalent to a legally marketed predicate device, leveraging existing safety and effectiveness standards.
Context for Roche Diagnostics
Roche Diagnostics frequently introduces new assays and platforms to its Elecsys portfolio, a prominent line of immunoassay solutions for a wide range of disease areas. The addition of an EBV VCA IgG assay strengthens its offerings in infectious disease testing, a market characterized by continuous demand for accurate and efficient diagnostic tools.
The clearance adds to Roche's broad diagnostic capabilities, addressing a common viral infection with established serological markers.
Further details regarding the specific performance characteristics, such as sensitivity and specificity data, or the specific patient populations for which the test is indicated, are expected to be released by Roche Diagnostics following this regulatory milestone. Commercial availability timelines and pricing have not been announced.
